FUS has enhanced the effectiveness of various HD therapies, such as siRNA, glial cell line-derived neurotrophic factor (GDNF), and adeno-associated virus (AAV) vector-based gene therapies, through effective BBB opening in animal models. Here, GDNF is linked to Huntington disease.